Diverse alterations associated with resistance to KRAS(G12C) inhibition

[1]  P. Jänne,et al.  99O_PR KRYSTAL-1: Activity and preliminary pharmacodynamic (PD) analysis of adagrasib (MRTX849) in patients (Pts) with advanced non–small cell lung cancer (NSCLC) harboring KRASG12C mutation , 2021 .

[2]  C. Rudin,et al.  Concurrent Mutations in STK11 and KEAP1 Promote Ferroptosis Protection and SCD1 Dependence in Lung Cancer , 2020, Cell reports.

[3]  P. Lito,et al.  Targeting KRAS(G12C): From Inhibitory Mechanism to Modulation of Antitumor Effects in Patients , 2020, Cell.

[4]  A. Abate,et al.  Single cell mutation analysis of clonal evolution in myeloid malignancies , 2020, Nature.

[5]  Davide Risso,et al.  Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition , 2020, Nature.

[6]  J. Fernandez-Banet,et al.  The KRASG12C Inhibitor, MRTX849, Provides Insight Toward Therapeutic Susceptibility of KRAS Mutant Cancers in Mouse Models and Patients. , 2019, Cancer discovery.

[7]  J. Desai,et al.  The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity , 2019, Nature.

[8]  P. Rodriguez-Viciana,et al.  SHOC2 complex-driven RAF dimerization selectively contributes to ERK pathway dynamics , 2019, Proceedings of the National Academy of Sciences.

[9]  J. Downward,et al.  SHOC2 phosphatase-dependent RAF dimerization mediates resistance to MEK inhibition in RAS-mutant cancers , 2019, Nature Communications.

[10]  P. Zarrinkar,et al.  KRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination with PI3K Inhibition , 2018, Clinical Cancer Research.

[11]  P. A. Futreal,et al.  High-throughput single-cell DNA sequencing of acute myeloid leukemia tumors with droplet microfluidics , 2018, Genome research.

[12]  P. Zarrinkar,et al.  Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor , 2018, Cell.

[13]  P. Poulikakos,et al.  New perspectives for targeting RAF kinase in human cancer , 2017, Nature Reviews Cancer.

[14]  Frank McCormick,et al.  RAS Proteins and Their Regulators in Human Disease , 2017, Cell.

[15]  Donavan T. Cheng,et al.  Mutational Landscape of Metastatic Cancer Revealed from Prospective Clinical Sequencing of 10,000 Patients , 2017, Nature Medicine.

[16]  Yi Liu,et al.  Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State. , 2016, Cancer discovery.

[17]  Neal Rosen,et al.  Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism , 2016, Science.

[18]  Donavan T. Cheng,et al.  Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology. , 2015, The Journal of molecular diagnostics : JMD.

[19]  Steven J. M. Jones,et al.  Comprehensive molecular profiling of lung adenocarcinoma , 2014, Nature.

[20]  Björn Usadel,et al.  Trimmomatic: a flexible trimmer for Illumina sequence data , 2014, Bioinform..

[21]  Roland Seifert,et al.  Faculty Opinions recommendation of K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. , 2013 .

[22]  Kevan M. Shokat,et al.  K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions , 2013, Nature.

[23]  Cole Trapnell,et al.  TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions , 2013, Genome Biology.

[24]  D. Bar-Sagi,et al.  RAS oncogenes: weaving a tumorigenic web , 2011, Nature Reviews Cancer.

[25]  M. DePristo,et al.  The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. , 2010, Genome research.

[26]  Gonçalo R. Abecasis,et al.  The Sequence Alignment/Map format and SAMtools , 2009, Bioinform..

[27]  Cole Trapnell,et al.  Ultrafast and memory-efficient alignment of short DNA sequences to the human genome , 2009, Genome Biology.

[28]  M. Ladanyi,et al.  Frequency and Distinctive Spectrum of KRAS Mutations in Never Smokers with Lung Adenocarcinoma , 2008, Clinical Cancer Research.

[29]  B. Taylor,et al.  V211D mutation in MEK1 causes resistance to MEK inhibitors in colon cancer. , 2019, Cancer discovery.

[30]  M. Berger,et al.  Abstract B015: An approach to suppress the evolution of resistance in BRAFV600E-mutant cancer , 2018 .